Tumor Necrosis Factor Receptor Superfamily Member 10B / DR5 (TNFRSF10B) Antibody
806€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Tumor Necrosis Factor Receptor Superfamily Member 10B / DR5 (TNFRSF10B) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx174979
tested applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Tumor Necrosis Factor Receptor Superfamily Member 10B / DR5 (TNFRSF10B) |
| Host | Mouse |
| Reactivity | Rat |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | DR5,CD262,KILLER,TRICK2,TRICKB,ZTNFR9,TRAILR2,TRICK2A,TRICK2B,TRAIL-R2,KILLER/DR5,Death receptor 5,TNF-related apoptosis-inducing ligand receptor 2 |
| Background | Antibody anti-TNFRSF10B |
| Status | RUO |
Descripción
TNFRSF10B (TNF receptor superfamily member 10b), also known as TRAIL-R2, DR5 (death receptor 5), or KILLER (Killer/DR5), is a cell surface receptor in the TNF receptor superfamily. It plays a crucial role in mediating apoptosis, especially in transformed or cancerous cells, through interaction with the TNF-related apoptosis-inducing ligand (TRAIL). Like other members of the death receptor family, TNFRSF10B is part of the body's natural mechanism for controlling cell growth, immune responses, and tumor suppression. TRAIL selectively targets cells exhibiting TNFRSF10B expression, making it a key pathway in immune surveillance and tumor inhibition, while leaving normal cells relatively unaffected. Due to its selective induction of apoptosis in abnormal cells, TNFRSF10B has become an important target in cancer therapeutics.
Related Products
Human TNFRSF10B (Tumor necrosis factor receptor superfamily member 10B) ELISA Kit
Ver Producto
TNFRSF10B-Specific antibody
Ver Producto